| RD13-02 / Nanjing Bioheng Biotech |
NCT05907603: Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML) |
|
|
| Recruiting | 1 | 18 | RoW | RD13-02 cell infusion | Kai Lin Xu，MD, Nanjing Bioheng Biotech Co., Ltd. | Neoplasms, Hematologic Neoplasms, Hematologic Diseases | 03/24 | 03/25 | | |
| Recruiting | 1 | 22 | RoW | RD13-02 cell infusion | He Huang, Nanjing Bioheng Biotech Co., Ltd. | Neoplasms, Hematologic Neoplasms, Neoplasms by Site, Hematologic Diseases | 03/24 | 05/25 | | |
NCT05902845: RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL |
|
|
| Recruiting | 1 | 12 | RoW | RD13-02 cell infusion | Xiaoyu Zhu, Nanjing Bioheng Biotech Co., Ltd. | Neoplasms, Hematologic Neoplasms, Hematologic Diseases | 04/24 | 04/25 | | |
NCT05895994: Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies |
|
|
| Recruiting | 1 | 18 | RoW | RD13-02 cell infusion | MEI HENG, Nanjing Bioheng Biotech Co., Ltd. | Neoplasms, Hematologic Neoplasms, Neoplasms by Site, Hematologic Diseases | 02/25 | 02/26 | | |
NCT05923541: RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies |
|
|
| Recruiting | 1 | 10 | RoW | RD13-02 cell infusion | Henan Cancer Hospital, Nanjing Bioheng Biotech Co., Ltd. | Hematologic Malignancies | 06/25 | 06/26 | | |
NCT05979792: Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma |
|
|
| Not yet recruiting | 1 | 35 | RoW | CAR-T Therapy | Zhao Weili | Peripheral T Cell Lymphoma | 08/25 | 12/25 | | |
